

The endothelial-to-mesenchymal transition process

Luz Marina Carrillo P. and Enrique Arciniegas C.*

Laboratorio de Microscopía Electrónica; Servicio Autónomo Instituto de Biomedicina, Facultad de Medicina, Universidad Central de Venezuela.

*Correspondence to: Enrique Arciniegas, PhD. Servicio Autónomo Instituto de Biomedicina; Universidad Central de Venezuela. Apartado de correos 4043, Carmelitas, Caracas 1010 Venezuela. Fax number: (58)-(212)-861-1258. E-mail: earciniegasbeta@yahoo.com

This work was supported by FONACIT Grant G2005000405

Recibido: 18 /09/ 2009

Aceptado:20/10/2009

Abstract

Endothelial-to-mesenchymal transition is a process through which certain endothelial cells lose endothelial characteristics and transform into mesenchymal cells or smooth muscle-like cells. Rapidly emerging data suggest that this process may have crucial roles during vascular development, cardiac fibrosis and intimal thickening formation observed in atherosclerosis and restenosis as well as in complex lesions associated with pulmonary hypertension, and during cancer progression. EndoMT entails growth factors and cytokines synthesis and secretion, activation of receptors, cytoskeleton reorganization, disassembly of the adherence junctions or loss of endothelial cell-cell contacts, change in cell shape and polarity, proteases secretion, extracellular matrix remodeling, cell detachment and cell migration and differentiation.

Here, we briefly review EndoMT keeping in mind that several questions still remain without answer.

Key words: endothelial-mesenchymal transition, vascular remodeling, intimal thickening, growth factors, β -catenin

Introduction

Blood vessels are not static structures. The vasculature undergoes continuous remodeling as part of its normal ageing and physiological function. Vascular remodeling, more precisely wall remodeling, is a dynamic process of structural and architectural alterations that occurs during the embryonic and the vasculature development as well as in the progression of arterial disease. This process involves cell growth, cell migration, apoptosis and degradation and reorganization in the extracellular matrix (ECM) composition and is regulated by forces that are associated with blood flow (hemodynamic forces), as well as by environmental and genetic factors^{1,2}. Pulmonary vascular remodeling is a process generally associated with pulmonary arterial hypertension that is characterized by perturbations of hemodynamic forces, including shear stress to which the endothelium is exposed. This process includes intimal thickening or intimal hyperplasia, medial thickness, and plexiform lesions, this last being the most complicated form of intimal thickening^{3,4}. In general, intimal thickening is defined as an increase in cell number residents within the innermost region of the vessel wall (intima) which occurs concomitantly with the degradation and reorganization of ECM components. It may also involve microenvironmental factors (e.g. cytokine and growth factors), cell migration and proliferation, and gene expression modulation^{5,6}. Currently, there is controversy regarding not only the nature and origin or the source of vascular smooth muscle cells (SMCs) involved in development⁷ and the cells that conform the intimal thickening⁸, but also regarding the mechanisms contributing to their formation. In this respect, recent studies have proposed different sources for intimal cells that include circulating hematopoietic cells or local vascular SMCs⁹. Other sources could be the endothelium by an endothelial-mesenchymal transition (EndoMT) process¹⁰ or epicardial cells⁷. Therefore, it is our intention to briefly review EndoMT, keeping in mind that several problems still remain without answer.

EndoMT process:


EndoMT is a process through which certain endothelial cells lose endothelial characteristics and transform into mesenchymal cells or SM-like cells (Fig. 1). EndoMT is now recognized as a phenomenon that occurs during cardiac fibrosis¹¹ and neointimal thickening formation observed in atherosclerosis and restenosis¹⁰, and that also occurs in complex lesions associated with pulmonary hypertension^{3,4} and with idiopathic portal hypertension¹². In addition to this role, recent evidence has also demonstrated that EndoMT is critical in heart and vascular development^{10,13}, hyperthrophic scarring¹⁴, kidney fibrosis¹⁵, and during cancer progression¹⁶. As in the transition of epithelial cells to an mesenchymal phenotype (EMT), EndoMT seems to progress through a series of important steps whose interdependence and order are not clear as yet^{10,17}. This complex process entails growth factors and cytokines synthesis and secretion, activation of receptors, cytoskeleton reorganization, disassembly of the adherence junctions or loss of endothelial cell-cell contacts, change in cell shape and polarity, proteases secretion, ECM remodeling, cell detachment and cell migration and differentiation¹⁰. Outstandingly, excessive signaling of growth factors or aberrant activation of tyrosine kinase as well as loss of epithelial cell-to-cell contacts have been consistently reported at EMT sites during development and disease¹⁷. Regarding the vascular endothelium, endothelial cell-to-cell contacts are maintained by adherens junctions mainly composed of vascular endothelial cadherin (VE-cadherin)^{18,19}. This transmembrane adhesive protein is linked to the actin cytoskeleton via cytoplasmic proteins called catenins, in particular β -catenin and p120-catenin^{18,19}. These molecules are generally related to the maintenance of cell-cell contacts and regulation of the intracellular signaling pathways that are implicated in cell growth, apoptosis, matrix and cytoskeletal remodeling^{18,19}. The architecture of this complex may be disrupted by tyrosine phosphorylation of both VE-cadherin and β -catenin involving specific tyrosine kinases¹⁸⁻²⁰. In this respect, there are reports showing that loss of endothelial cell-cell contacts and cell shape and polarity may occur in response to mechanical injury, shear stress, and / or cross talk of a variety of growth factors including fibroblast-growth factor-2 (FGF-2), transforming growth factor- β (TGF β), and insulin-like growth factor II (IGFII)²¹⁻²³ and that such events are necessary in the progression of EndoMT (Fig. 2). Nevertheless, how these factors and signals generated may cause the endothelial transformation is still matter of debate²⁴. As mentioned, in the EMT and EndoMT processes some soluble growth factors participate actively. For instance, IGFII which, apart from being considered important in wound healing, cancer progression, pulmonary fibrosis, angiogenesis, and atherosclerosis lesions²⁵⁻²⁸ is also considered to participate during embryonic development²⁹. This growth factor binds the insulin-like growth factor receptor I (IGFIR) initiating several signaling cascades that would lead to the dissociation of β -catenin from VE-cadherin allowing its relocation to the cytoplasm and the nucleus where it modulates gene transcription^{23,24}. The interpretation of these results is complex, but we can speculate that IGFIR activation

might be involved in the regulation of endothelial cell-cell contacts and cell polarity and the eventual activation of some transcription factors contributing to the generation of signaling cascades that govern the EndoMT process²⁴. Notably, the activation of nuclear factor kappa light chain gene enhancer in B cells (NF κ B), a transcriptional factor that regulates the expression of hundred genes and whose activation proceeds rapidly and depends on the type and intensity of the stimulus has been correlated with the loss of VE-cadherin and redistribution of β -catenin and subsequent expression of α -smooth muscle actin (α -SM actin) during the embryonic aortic wall remodeling and the EndoMT³⁰. A link between such activation and the expression of some metalloproteinases (MMPs) during the EndoMT was also proposed³⁰. This assumption was based on studies related to hemodynamic alterations which had demonstrated that an increased expression of MMP2 and MMP9 occurred during intimal thickening formation, some of them indicating that the translocation of NF κ B correlates with the expression and activation of certain MMPs in endothelial cells³¹. However, little work has been done examining specifically the role of these molecules in the EndoMT process.


Another important growth factor is epidermal growth factor (EGF) which acts by binding to specific receptor tyrosine kinases, the EGF receptor family (EGFR), provoking its homo and/or heterodimerization and tyrosine phosphorylation and initiating various important signal transduction pathways³². Upon binding of EGF, receptor clustering and endocytosis take place followed by recycling back of the ligand-receptor complex to the cell surface or degradation. After internalization, nuclear translocation of the receptors may also occur to regulate gene expression³⁴. EGF ligands include: EGF-like growth factor, transforming growth factor- α (TGF- α), heparin binding EG-like growth factor (HBEGF), amphiregulin (AREG), betacellulin (BTC), epiregulin (EREG), epigen (EPGN), and four neuregulins (NREGS)^{32,33}. As mentioned, these ligands are recognized by four members of the EGFR family: EGFR (HER1), Neu (ErbB2, HER2), ErbB3 (HER3) and ErbB4 (HER4)^{32,33}. These receptors regulate important cellular processes, including cell proliferation, apoptosis, cell polarity, differentiation, migration and invasion³⁵. Importantly, regulation of cell-cell contacts by EGF/ErbB1 via E-cadherin and cytoskeleton has been proposed to correlate with tumor progression and metastasis and EMT^{36,37}. Overexpression of EGFR has also been suggested to contribute to the development of arterial hypertension³⁸. Also, overexpression of EGF and activation of NF κ B has been documented³⁹. Moreover, expression of EGF and HB-EGF as well as of their respective ligands, ErbB1 and ErbB2, has been detected in the intimal thickening and medial SMCs of atherosclerotic lesions, whereas little or not presence of these molecules is observed in the cells of healthy vessels^{40,41}. Of note, a study in transformation of endocardial endothelial cells into mesenchymal cells demonstrated the presence of an ErbB2-ErbB3 heterodimer suggesting that this complex is required for the normal endocardial cushion tissue development⁴². Nevertheless, the cellular and molecular mechanisms by which EGF / EGFR exert these actions remain to be elucidated.

In addition to IGFII and EGF, the vascular endothelial growth factor (VEGF) and its receptor (VEGFR) has also been proposed to participate in vasculogenesis, angiogenesis, atherosclerosis, restenosis, and tumor progression⁴³⁻⁴⁵, processes where both EMT and EndoMT are involved. For instance, VEGFR was found to form

a complex with VE-cadherin, β -catenin in vascular endothelial cells enhancing VEGF signaling⁴⁶. Induction of EMT by EGFR in tumor progression in pancreatic cancer has also been proposed⁴⁷. However, studies focused on the role of VEGF/VEGFR signaling in the EndoMT process are scarce.



Confocal laser scanning microscope fluorescence (CLSM) images of vWf and α -SM actin in a monolayer of aortic embryonic endothelial cells attached to fibronectin after 48 h in culture in complete medium. Strong positivity for vWf (red) in punctated and granular pattern typical of endothelial cells, and for α -SM actin (green) delineating cellular margin are observed. Double immunofluorescence of the same field shows some of the cells exhibiting immunoreactivity for both vWf and α -SM actin (arrows, merged). Scale bar = 20 μ m.



CLSM fluorescence images of both β - and p120-catenins in a monolayer of embryonic endothelial cells attached to fibronectin after 22 h in culture.

Strong positivity for both β -catenin (a) and p-120 catenin (c) is observed at the plasma membrane of endothelial cells that display a cobblestone appearance, whereas this expression and distribution appeared altered in separating, detaching and migrating cells (b,d). Note that β -catenin immunoreactivity is also detected in the nucleus and cytoplasm of some migrating cells (arrow).

In this review we intend to present the current state of knowledge regarding the EndoMT process which occurs not only during embryonic development but also in the pathogenesis of various diseases that take place not only in adult life but also throughout childhood and adolescence. In other words, we provides an excellent example of how the morphogenesis is recapitulated at least in part, in vascular pathologies, repair of injured tissues and during tumor progression.

Finally, as it has been proposed by other authors, we believe that the EndoMET would represent a therapeutic target in atherosclerosis, tumor angiogenesis, and other disorders^{10,11,16}.

References

- Hahn C, Schwartz MA. Mechanotransduction in vascular physiology and atherogenesis. *Nat Rev* 2009; 10: 53-62.
- Davies PF. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. *Nat Clin Pract Cardiovasc Med* 2009; 6: 16-26.
- Stewart S, Rassi D. Advances in the understanding and classification of pulmonary hipertension. *Histopathology* 2009; 54: 104-116.
- Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR et al. Cellular and molecular basis of pulmonary arterial hipertension. *J Am Coll Cardiol* 2009; 54: S20-S31.
- Nakashima Y, Xiang Cheng Y, Kinukawa N, Sueishi K. Distributions of diffuse intimal thickening in human arteries: Preferential expresion in atherosclerosis-prone arteries from an early age. *Virchows Arch* 2002; 441: 279-88.
- Nakashima Y, Wight TN, Sueishi K. Early atherosclerosis in humans: Role of diffuse intimal thickening and extracellular matrix proteoglycans. *Cardiovasc Res.* 2008; 79: 14-23.
- Majesky MW. Developmental basis of vascular smooth muscle diversity. *Arterioscler Thromb Vasc Biol* 2007; 27: 1-11.
- Hoofnagle MH, Thomas JA, Wamhoff BR, Owens G. Origin of neointimal smooth muscle: We've come full circle. *Arterioscler Thromb Vasc Biol* 2006; 26: 2579-2581.
- Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. *Nat Med* 2002; 8: 403-409.
- Arciniegas E, Frid MG, Douglas IS, Stenmark KR. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hipertension. *Am J Physiol Lung Cell Mol Physiol* 2007; 293: L1-L8.
- Goumans MJ, van Zonneveld AJ, Dijke PT. Transforming growth factor β -induced endothelial-to-mesenchymal transition: A switch to cardiac fibrosis? *Trends Cardiovasc Med* 2008; 18: 293-298.
- Kitao A, Sato Y, Kitamura SS, Harada K, Sasaki M, Morikawa H, et al. Endothelial to mesenchymal transition via transforming growth factor- β 1/ smad activation is associated with portal venous stenosis in idiopathic portal hipertension. *Am J Pathol* 2009; 175: 616-626.
- Mironov V, Visconti RP, Markwald RR. On the role of shear stress in cardiogenesis. *Endothelium* 2005; 12: 259-261.
- Xi-Qiao W, Ying-Kai L, Chun Q, Shu-Liang L. Hyperactivity of fibroblasts and functional regression of endothelial cells contributes to microvessel occlusion in hypertrophic sparring. *Microvasc Res* 2009; 77: 204-211.
- Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. *J Am Soc Nephrol* 2008; 19: 2282-2287.
- Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. *British J Cancer* 2008; 99: 1375-1379.
- Baum B, Settleman J, Quinlan MP. Transitions between epithelial and mesenchymal states in development and disease. *Seminar Cell Dev Biol* 2008; 19: 294-308.
- Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. *J Cell Sci* 2008; 121: 2115-2122.
- Dejana E, Lasserre ET, Weinstein BM. The control of vascular integrity by endothelial cell junctions: Molecular basis and pathological implications. *Dev Cell* 2009; 16: 209-221
- Mukherjee S, Tessema M, Wandinger-Ness A. Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function. *Circ Res* 2006; 98: 743-756.
- Frid MG, Kale VA, Stenmark KR. Mature vascular endothelium can give rise to smooth muscle cells via endothelial mesenchymal transdifferentiation: in vitro analysis. *Circ Res* 2002; 90: 1189-1196.
- Liebner S, Catellino A, Gallini R, Rudini N, Iurlaro M, Piccolo S, et al. β -catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. *J Cell Biol* 2004; 166: 359-367.
- Arciniegas E, Neves YC, Carrillo LM. Potential role for insulin-like growth factor II and vitronectin in the endothelial-mesenchymal transition process. *Differentiation* 2006; 74: 277-292.
- Arciniegas E, Candelle D. An alternate insulin-like factor I receptor signaling pathway for the progression of endothelial-mesenchymal transition. *Bioscience Hypotheses* 2008; 1: 312-319.
- Perks CM, Holly JM. The insulin-like growth factor (IGF) family and breast cancer. *Breast Dis* 2009; 18: 45-60.
- Chao W, D' Amore PA. IGF2: Epigenetic regulation and role in development and disease. *Cytokine Growth Factor Rev.* 2008; 19: 111-120.
- Zaina S, Nilsson J. Insulin-like growth factor II and its receptors in atherosclerosis and in conditions predisposing to atherosclerosis. *Curr Opin Lipidol* 2003; 14: 483-489.
- Hsu E, Feghali-Bostwick, CA. Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase and phosphatidylinositol-3 kinase dependent pathways. *Am J Pathol* 2008; 172: 1580-1590.
- Louvi A, Accili D, Efstratiadis A. Growth promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. *Dev Biol* 1997; 189: 33-48.
- Arciniegas E, Carrillo LM, De Sanctis JB, Candelle D. Possible role of NF κ B in the embryonic vascular remodeling and the endothelial mesenchymal transition process. *Cell Adhesion & Migration* 2008; 2: 1-13.
- Sun HW, Li CJ, Chen, HQ, Lin HL, Lv HX, Zhang M. Involvement of integrins, MAPK and NF- κ B in regulation of the shear stress-induced MMP-9 expression in endothelial cells. *Biochem Biophys Res Commun* 2007; 353: 152-158.
- Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: Receptor heterodimerization in development and cancer. *EMBO J* 2000; 19: 3159-3167.
- Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. *J Cell Physiol* 2009; 218: 460-466.

34. Lin SY, Makino K, Xia W, Matin A, Wen Yong, Kwong KY et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. *Nat Cell Biol* 2001; 3: 802-808.
35. Feigin ME, Muthuswamy SK. ErbB receptors and cell polarity: New pathways and paradigms for understanding cell migration and invasion. *Exp Cell Res* 2009; 315: 707-716.
36. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, et al. The role of the EGFR signaling in tumor microenvironment. *J cell Physiol* 2008; 214: 559-567.
37. Ackland ML, Newgreen DF, Fridman M, Watham MC, Arvanitis A, Minichiello J, et al. Epidermal growth factor induced epithelio-mesenchymal transition in human breast carcinoma cells. *Lab Invest* 2003; 83: 435-448.
38. Beltowski J, Lowicka E. EGF receptor as a drug target in arterial hypertension. *Mini Rev Med Chem* 2009; 9: 526-538.
39. Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB. Epidermal growth factor (EGF) activates nuclear factor-kB through Ikb α kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of Ikb α . *Oncogene* 2007; 26: 7324-7332.
40. Dreux AC, Lamb DJ, Modjtahedi H, Ferns GA. The epidermal growth factor receptors and their family of ligands: Their putative role in atherogenesis. *Atherosclerosis* 2006; 186: 38-53.
41. Zhang H, Sunnarborg SW, McNaughton K, Johns TG, Lee DC, Faber JE. Heparin-binding epidermal growth factor-like growth factor signaling in flow-induced arterial remodeling. *Circ Res* 2008; 102: 1275-1285.
42. Camenisch TD, Schroeder JA, Bradley J, Klewer SE, McDonald JA. Heart valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. *Nat Med* 2002; 8: 850-855.
43. Anderson-Berry A, O'Brien EA, Bleyl S, Lawson A, Gundersen N, Ryssman D, et al. Vasculogenesis drives pulmonary vascular growth in the developing chick embryo. *Dev Dyn* 2005; 233: 145-153.
44. Simons M. VEGF and restenosis: The rest of the story. *Arterioscler Thromb Vasc Biol.* 2009; 29: 439-440.
45. Wu Y, Zhu Z. Vascular endothelial growth factor receptor-1, a therapeutic target in cancer, inflammation and other disorders. *Curr Med Chem* 2009; 16: 2890-2898.
46. Shay-Salit A, Shushy M, Wolfovitz E, Yahav H, Breviario F, Dejana E, et al. VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells. *PNAS* 2002; 99: 9462-9467.
47. Yang AD, Camp ER, Fan F, Shen L, Gray MJ, Liu W, et al. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. *Cancer Res* 2006; 66: 46-51.

Archivos Venezolanos de Farmacología y Terapéutica

Órgano Oficial de las Sociedades Venezolanas
de Farmacología y de Farmacología Clínica y Terapéutica

Revista Internacional, arbitrada por expertos, de circulación internacional con áreas de interés en ciencias básicas y clínicas en Bioquímica, Fisiología, Fisiopatología y Farmacología, como también en Terapéutica médica, ensayos clínicos, ensayos toxicológicos, fármaco vigilancia.

Dando relevancia a estudios farmacológico clínicos y terapéuticos de drogas nuevas en hipertensión, enfermedad coronaria, diabetes, obesidad, síndrome metabólico, infecciones locales y sistémicas, procesos articulares degenerativos, enfermedades crónicas del sistema nervioso central.

Envíe su manuscritos de revisión, originales, cartas al editor al e-mail:

manuel.veloscom@gmail.com
veloscom@cantv.net

AVFT esta indexada en:

- 1) LIVECS
- 2) LILACS
- 3) BIREME
- 4) REDALYC
- 5) PERIODICA (UNAM, MEXICO)
- 7) LATINDEX
- 8) EXTRAMED
- 9) SCIELO

www.scielo.org.ve

www.archivosvenezolanosdefarmacologiyterapiutica.com